WASHINGTON — The Coalition for a Prosperous America (CPA) today sent a letter to Dr. Robert Califf, Commissioner of the Food and Drug Administration (FDA), over the agency’s controversial decision to allow the continued sale of generic drugs from India despite faulty data and a lack of proof of therapeutic equivalence. FDA did not prohibit…
Senator Burr warned the FDA that until the Senate is okay with their response to the infant formula crisis, and present a plan to prevent it in the future, the Generic Drug User Fee Authorization bill might be put on hold.
WASHINGTON — The Coalition for a Prosperous America (CPA) urged President Joe Biden to address the decades of dereliction of duty by the Food and Drug Administration (FDA) to ensure our nation has a safe, affordable, and readily accessible supply of generic and other essential medicines. Earlier this year, CPA launched Americans for Safe Drugs,…
CPA sent the following letters to the Chairs and Ranking Members of the Senate Health, Education, Labor, and Pensions Committee and the House Energy and Commerce Committee regarding the Food and Drug Administration’s (FDA) lack of action on addressing shortages of essential and lifesaving products, including critical generic medicines and baby formula, and the agency’s…
CPA sent the following letter to President Joe Biden requesting that his administration take action to address the failures of the Food and Drug Administration (FDA) to ensure Americans have access to safe, affordable, and reliable medicine. Dear President Biden: We write to you regarding the crisis facing our nation as a result of decades…
The U.S. China Economic and Security Review Commission discussed the tight-linked China-India pharmaceutical supply chain, and tossed aside the notion that sweeping trade deals with India and the region are good ideas.
The Health subcommittee of the House Energy and Commerce Committee have moved the FDA user-fee reauthorization bill to final committee. Chairwoman Eshoo says it is on track for September approval.
A House committee hearing on the FDA focused on diversity in clinical trials, fast approval for cancer drugs, and no word on foreign vs domestic generic pharmaceutical labs.